A Phase Ⅰb/Ⅱ Study of Fruquintinib Combined With Capecitabine in the First-line Maintenance Treatment of RAS/BRAF Wild-type Metastatic Colorectal Cancer
Latest Information Update: 18 Oct 2023
At a glance
- Drugs Capecitabine (Primary) ; Fruquintinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Oct 2023 According to a HUTCHMED media release, new and updated clinical data from this study will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain
- 04 Aug 2020 New trial record